UNIQURE NV

QURENASDAQ

🏆 #1391 by market capEarnings Nov 9US Equity

$789.72▼ $12.95 (−1.64%)

Simulated price

1h—

24h▼ 1.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$3.12B

Small Cap

📈Revenue Growth (YoY)

+30.2%

High Growth

📊Gross Margin

92.5%

High

💵FCF Margin

199.2%

Strong

⚖️P/S Ratio

172.5x

Expensive

Otter Score

Weak

No chart data available for QURE.

Trading Snapshot

Day Range: $785.47 – $793.79
52-Week Range: $8.73 – $71.50
Volume: $2.42B
Avg Volume: $2.80B
Shares Outstanding: 69.4M
Next Earnings: Oct 16, 2026

Fundamentals Snapshot

Annual Revenue: $16M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: 172.5x
EPS (TTM): $-4.05
Dividend Yield: —

Why Investors Own QURE

✓High-growth profile — revenue up -4.1% YoY with expanding US Equity exposure.
✓Healthy economics — 35% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$16M▼ −2.7% YoY

Gross Margin (TTM)

35.2%▲ +1.0% YoY

Operating Income (TTM)

$2M▼ −2.7% YoY

Free Cash Flow (TTM)

$4M▼ −2.7% YoY

About UNIQURE NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

🦦